Bristol-Myers Squibb Company Website

Bristol-Myers Squibb Company

NYSE-BMY

Basic

  • Market Cap

    $85B

  • EV

    $132.47B

  • Shares Out

    2,027.1M

  • Revenue

    $45.53B

  • Employees

    34,100

Margins

  • Gross

    76.03%

  • EBITDA

    39.91%

  • Operating

    18.3%

  • Pre-Tax

    -12.84%

  • Net

    -13.5%

  • FCF

    27.47%

Returns (5Yr Avg)

  • ROA

    3.35%

  • ROTA

    -29.44%

  • ROE

    10.09%

  • ROCE

    11.34%

  • ROIC

    10.44%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $53.19

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $9,670M

  • Net Debt

    $47.42B

  • Debt/Equity

    3.47

  • EBIT/Interest

    6.39

Growth (CAGR)

  • Rev 3Yr

    2.08%

  • Rev 5Yr

    14.35%

  • Rev 10Yr

    10.78%

  • Dil EPS 3Yr

    2.8%

  • Dil EPS 5Yr

    -0.89%

  • Dil EPS 10Yr

    5.67%

  • Rev Fwd 2Yr

    1.16%

  • EBITDA Fwd 2Yr

    1.15%

  • EPS Fwd 2Yr

    -4.05%

  • EPS LT Growth Est

    -5.33%

Dividends

  • Yield

  • Payout

    -78.03%

  • DPS

    $2.34

  • DPS Growth 3Yr

    7.57%

  • DPS Growth 5Yr

    7.63%

  • DPS Growth 10Yr

    5.12%

  • DPS Growth Fwd 2Yr

    4.58%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

26,145

42,518

46,385

46,159

45,006

45,534

Total Revenues % Chg.

15.9%

62.6%

9.1%

-0.5%

-2.5%

-0.7%

Cost of Goods Sold, Total

7,898

11,773

9,940

9,781

10,518

10,916

Gross Profit

18,247

30,745

36,445

36,378

34,488

34,618

Selling General & Admin Expenses, Total

4,969

7,618

7,655

7,703

7,678

7,884

R&D Expenses

6,066

10,048

10,195

9,201

9,112

9,252

Amortization of Goodwill and Intangible Assets

1,135

9,688

10,023

9,595

9,047

9,148

Other Operating Expenses, Total

12,170

27,354

27,873

26,499

25,837

26,284

Operating Income

6,077

3,391

8,572

9,879

8,651

8,334

Interest Expense, Total

-898

-1,381

-1,303

-1,205

-1,161

-1,304

Interest And Investment Income

464

121

39

171

449

530

Net Interest Expenses

-434

-1,260

-1,264

-1,034

-712

-774

Income (Loss) On Equity Invest.

-5

72

231

-108

-38

13

Currency Exchange Gains (Loss)

-13

23

32

148

160

105

Other Non Operating Income (Expenses)

1,496

1,528

1,708

1,818

2,079

1,972

EBT, Excl. Unusual Items

7,121

3,754

9,279

10,703

10,140

9,650

Restructuring Charges

-564

-538

-160

-144

-535

-708

Merger & Related Restructuring Charges

-1,072

-717

-564

-863

-326

-1,054

Gain (Loss) On Sale Of Investments

357

1,157

514

-693

-122

84

Gain (Loss) On Sale Of Assets

1,168

55

9

211

Asset Writedown

-15

-98

-107

-87

In Process R&D Expenses

-12,533

-1,159

-815

-913

-13,787

Legal Settlements

-77

194

-82

-178

-10

63

Other Unusual Items

-1,943

1,757

261

-410

313

-7

EBT, Incl. Unusual Items

4,975

-6,871

8,098

7,713

8,440

-5,846

Income Tax Expense

1,515

2,124

1,084

1,368

400

289

Earnings From Continuing Operations

3,460

-8,995

7,014

6,345

8,040

-6,135

Minority Interest

-21

-20

-20

-18

-15

-13

Net Income

3,439

-9,015

6,994

6,327

8,025

-6,148

Net Income to Common Incl Extra Items

3,439

-9,015

6,994

6,327

8,025

-6,148

Net Income to Common Excl. Extra Items

3,439

-9,015

6,994

6,327

8,025

-6,148

Total Shares Outstanding

2,251

2,244

2,176

2,098

2,021

2,027

Weighted Avg. Shares Outstanding

1,705

2,258

2,221

2,130

2,069

2,050

Weighted Avg. Shares Outstanding Dil

1,712

2,258

2,245

2,146

2,078

2,050

EPS

2

-4

3.1

3

3.9

-3

EPS Diluted

2

-4

3.1

3

3.9

-3

EBITDA

7,798

13,824

19,329

20,161

18,420

18,172

Effective Tax Rate

30.5%

-30.9%

13.4%

17.7%

4.7%

-4.9%